Dapa-hf Trial And Detailing Guide
.
Questions and Answers
- 1.
DAPA-HF stands for
- A.
The Dapagliflozin and prevention of heart failure trial
- B.
The Dapagliflozin and prevention of adverse events in heart failure trial
- C.
The Dapagliflozin and adverse outcomes in heart failure trial
- D.
The Dapagliflozin and prevention of adverse outcomes in heart heart failure trial
Correct Answer
D. The Dapagliflozin and prevention of adverse outcomes in heart heart failure trial -
- 2.
The total number of Indian patients in DAPA HF trial were:
- A.
297
- B.
255
- C.
329
- D.
237
Correct Answer
D. 237 -
- 3.
Median followup in DAPA HF was ______ Months
- A.
18.2
- B.
18.4
- C.
16.2
- D.
20.4
Correct Answer
A. 18.2Explanation
The median follow-up in the DAPA HF study was 18.2 months. This means that half of the participants in the study were followed up for less than 18.2 months and half were followed up for more than 18.2 months. This measure of central tendency provides an indication of the duration of the study and the length of time participants were monitored for.Rate this question:
-
- 4.
The primary composit outcome by Dapa was ______% RRR in DAPA HF trial
- A.
30
- B.
25
- C.
19
- D.
26
Correct Answer
D. 26Explanation
The primary composite outcome achieved by Dapa in the DAPA HF trial was a 26% relative risk reduction (RRR). This means that the intervention implemented by Dapa resulted in a significant reduction in the risk of the primary composite outcome compared to the control group. The specific details of the primary composite outcome are not provided in the question, but the answer suggests that the intervention was effective in reducing the risk by 26%.Rate this question:
-
- 5.
Worsening HF event showed ______% RRR in DAPA HF trial
- A.
16
- B.
26
- C.
30
- D.
35
Correct Answer
C. 30Explanation
The correct answer is 30. This indicates that in the DAPA HF trial, there was a 30% Relative Risk Reduction (RRR) in worsening HF events. This means that the trial showed a significant reduction in the risk of worsening heart failure events by 30% compared to the control group.Rate this question:
-
- 6.
In DAPA HF trial the NNT was _____ for primary composite outcome
- A.
21
- B.
35
- C.
14
- D.
20
Correct Answer
A. 21Explanation
The NNT (Number Needed to Treat) refers to the number of patients that need to be treated in order to prevent one additional outcome event. In the DAPA HF trial, the NNT for the primary composite outcome was 21. This means that for every 21 patients treated, one additional outcome event was prevented.Rate this question:
-
- 7.
DAPA HF secondary outcome CV death or HF hospitalisation was ____%
- A.
35
- B.
20
- C.
15
- D.
25
Correct Answer
D. 25Explanation
The correct answer is 25. This suggests that in the study, the secondary outcome of cardiovascular death or heart failure hospitalization occurred in 25% of the participants. This indicates that a significant proportion of individuals experienced either cardiovascular death or were hospitalized for heart failure during the study period.Rate this question:
-
- 8.
Dapagliflozin shown _____ points increase in KCCQ total symptom score
- A.
3.0
- B.
2.2
- C.
2.8
- D.
2.6
Correct Answer
C. 2.8Explanation
Dapagliflozin has been shown to increase the KCCQ total symptom score by 2.8 points.Rate this question:
-
- 9.
One of the component of primary outcome CV death ____% RRR
- A.
20
- B.
16
- C.
18
- D.
30
Correct Answer
C. 18Explanation
The correct answer is 18. This indicates that there was an 18% relative risk reduction in cardiovascular death when comparing the intervention group to the control group. This means that the intervention had a significant impact in reducing the risk of cardiovascular death by 18% compared to not receiving the intervention.Rate this question:
-
- 10.
Change in NT pro BNP from baseline to 8 months was ______ pg/ml with dapagliflozin
- A.
-303
- B.
-450
- C.
-351
- D.
-456
Correct Answer
A. -303Explanation
The given correct answer for this question is -303. This indicates that there was a decrease of 303 pg/ml in NT pro BNP levels from baseline to 8 months with dapagliflozin.Rate this question:
-
- 11.
Primary composite outcome in diabetic subgroup was ___% RRR
- A.
22
- B.
27
- C.
26
- D.
25
Correct Answer
D. 25Explanation
The correct answer is 25. This suggests that the primary composite outcome in the diabetic subgroup had a 25% relative risk reduction (RRR). This means that compared to the control group, the diabetic subgroup had a 25% lower risk of experiencing the primary composite outcome.Rate this question:
-
- 12.
Primary composite outcome in non diabetic subgroup was ______% RRR
- A.
26
- B.
27
- C.
15
- D.
30
Correct Answer
B. 27Explanation
The correct answer is 27. This means that the primary composite outcome in the non-diabetic subgroup had a relative risk reduction (RRR) of 27%. This implies that the intervention or treatment being studied was able to reduce the risk of the primary composite outcome by 27% in the non-diabetic subgroup compared to the control group.Rate this question:
-
- 13.
UTI and GTI there was ______ between DAPA and placebo
- A.
Higher
- B.
Lower
- C.
No statistical significance
- D.
Significant
Correct Answer
C. No statistical significanceExplanation
The given correct answer suggests that there was no statistical significance between DAPA and placebo in terms of UTI and GTI. This means that the difference in outcomes between the two groups was not significant enough to conclude that DAPA had a greater or lesser effect compared to the placebo. The lack of statistical significance indicates that any observed differences could be due to chance rather than a true effect of the treatment.Rate this question:
-
- 14.
In DAPA HF trial ______% patients have recieved ARNI
- A.
15
- B.
11
- C.
12
- D.
20
Correct Answer
B. 11Explanation
In the DAPA HF trial, 11% of the patients have received ARNI.Rate this question:
-
- 15.
______ is a series of mechanistic studies evaluating the impact of Dapagliflozin 10mg
- A.
Dapa studies
- B.
Dapa trials
- C.
Dapa Mech
- D.
Dapa World
Correct Answer
C. Dapa MechExplanation
The given correct answer, "Dapa Mech," refers to a series of mechanistic studies that aim to evaluate the impact of Dapagliflozin 10mg. These studies are focused on understanding the mechanisms of action and how Dapagliflozin affects the body.Rate this question:
-
- 16.
True OR False Hematocrit levels were increased with dapagliflozin in subgroups of diabetes and non diabetes?
- A.
True
- B.
False
Correct Answer
A. TrueExplanation
Dapagliflozin is a medication used to treat diabetes by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. Studies have shown that dapagliflozin can also increase hematocrit levels, which is the percentage of red blood cells in the blood. This effect has been observed in both diabetes and non-diabetes subgroups, indicating that dapagliflozin can increase hematocrit levels regardless of the presence of diabetes. Therefore, the statement "Hematocrit levels were increased with dapagliflozin in subgroups of diabetes and non-diabetes" is true.Rate this question:
-
- 17.
What is the distribution of patients by eGFR of >60ml and <60ml in DAPA HF study?
- A.
80.0%, 20.0%
- B.
40.1% , 59.9%
- C.
35.0% , 65.2%
- D.
59.4% , 40.6%
Correct Answer
D. 59.4% , 40.6%Explanation
The correct answer is 59.4%, 40.6%. This suggests that in the DAPA HF study, 59.4% of patients had an eGFR greater than 60ml, while 40.6% of patients had an eGFR less than 60ml.Rate this question:
-
- 18.
Dapagliflozin consistently reduce the primary endpoint regardless of NT-proBNT quartiles at base line True OR False?
- A.
True
- B.
False
Correct Answer
A. TrueExplanation
The statement is true because dapagliflozin consistently reduces the primary endpoint, regardless of the NT-proBNT quartiles at baseline. This means that regardless of the initial levels of NT-proBNT, dapagliflozin is effective in reducing the primary endpoint.Rate this question:
-
- 19.
In DAPA HF trial safety parameters of major hypoglycemia, DKA, amputation was ______ between DAPA vs Placebo
- A.
Higher
- B.
Significant
- C.
Lower
- D.
No statistical difference
Correct Answer
D. No statistical differenceExplanation
The given answer suggests that there was no significant difference in the safety parameters of major hypoglycemia, DKA, and amputation between the DAPA group and the placebo group in the DAPA HF trial. This means that the occurrence of these adverse events was similar in both groups, indicating that the use of DAPA did not significantly increase or decrease the risk of these safety concerns compared to the placebo.Rate this question:
-
- 20.
In primary composite endpoint _____% ARR was seen dapagliflozin arm
- A.
4.9
- B.
4.5
- C.
6.0
- D.
5.2
Correct Answer
A. 4.9Explanation
The correct answer is 4.9. This suggests that in the dapagliflozin arm, there was a 4.9% absolute risk reduction in the primary composite endpoint. This means that dapagliflozin was able to significantly reduce the risk of the primary endpoint by 4.9% compared to the control group.Rate this question:
-
- 21.
In patients with eGFR<60, primary composite outcome was ______% shown by Dapa vs placebo
- A.
26%
- B.
24%
- C.
28%
- D.
27%
Correct Answer
C. 28%Explanation
In patients with an estimated glomerular filtration rate (eGFR) less than 60, the primary composite outcome was shown to be 28% when comparing the use of Dapa (presumably a medication) versus a placebo.Rate this question:
-
- 22.
How many %age patients were diabetic vs non diabetic
- A.
45 vs 55
- B.
60 vs 40
- C.
70 vs 30
- D.
80 vs 20
Correct Answer
A. 45 vs 55Explanation
The answer is 45 vs 55 because it indicates that out of the total number of patients, 45% were diabetic and 55% were non-diabetic.Rate this question:
-
- 23.
The benefits of reduced CV death and hHF was seen as early as ____ days
- A.
25
- B.
30
- C.
28
- D.
10
Correct Answer
C. 28Explanation
The benefits of reduced cardiovascular death and heart failure hospitalization were observed within 28 days. This suggests that the intervention or treatment being studied had a relatively quick and positive impact on these outcomes. The shorter timeframe also indicates that the intervention may be effective in preventing serious cardiovascular events and reducing the burden of heart failure on patients.Rate this question:
-
- 24.
Forxiga can also be used in patients with eGFR of greater than equal to 30ml True OR False
- A.
True
- B.
False
Correct Answer
A. TrueExplanation
Forxiga can be used in patients with an estimated glomerular filtration rate (eGFR) of greater than or equal to 30ml. This means that the medication is suitable for individuals with a relatively healthy kidney function. It is important to note that Forxiga should not be used in patients with severe renal impairment or end-stage renal disease. Therefore, the statement "True" indicates that Forxiga can be used in patients with an eGFR of greater than or equal to 30ml.Rate this question:
-
Back to top